Loss of FBP1 facilitates aggressive features of hepatocellular carcinoma cells through the Warburg effect

Reprogrammed metabolism has been identified as an emerging hallmark in cancer cells. It has been demonstrated that fructose-1, 6-bisphosphatase 1 (FBP1) as a rate-limiting enzyme in gluconeogenesis plays critical roles in tumor initiation and progression in several cancer types. However, function of...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Carcinogenesis (New York) 2017-02, Vol.38 (2), p.134
Hauptverfasser: Yang, Juan, Wang, Cun, Zhao, Fengbo, Luo, Xiaoying, Qin, Meilin, Arunachalam, Einthavy, Ge, Zhouhong, Wang, Ning, Deng, Xuan, Jin, Guangzhi, Cong, Wenming, Qin, Wenxin
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue 2
container_start_page 134
container_title Carcinogenesis (New York)
container_volume 38
creator Yang, Juan
Wang, Cun
Zhao, Fengbo
Luo, Xiaoying
Qin, Meilin
Arunachalam, Einthavy
Ge, Zhouhong
Wang, Ning
Deng, Xuan
Jin, Guangzhi
Cong, Wenming
Qin, Wenxin
description Reprogrammed metabolism has been identified as an emerging hallmark in cancer cells. It has been demonstrated that fructose-1, 6-bisphosphatase 1 (FBP1) as a rate-limiting enzyme in gluconeogenesis plays critical roles in tumor initiation and progression in several cancer types. However, function of FBP1 in hepatocellular carcinoma (HCC) is still not clear. In this study, we observed that the expression of FBP1 was obviously downregulated in the cell lines and tissues of HCC. Downregulation of FBP1 in HCC tissues was correlated with a lower overall survival rate and had a relatively higher tendency of tumor recurrence (n = 224). Silencing FBP1 could significantly promote colony formation, proliferation and metastasis of HCC cells, while ectopic overexpression of FBP1 resulted in impaired abilities of colony formation, proliferation and metastasis in vitro and in vivo. Mechanistically, silencing FBP1 facilitated glycolysis in HCC cell lines, which may be responsible for aggressiveness of HCC cells. We further found that targeting the Warburg effect using the specific inhibitor FX11 could suppress the aggressiveness of HCC cells which was mediated by loss of FBP1. These findings indicate that FBP1 appears to be a tumor suppressor in HCC. Strategies to restore the levels and activities of FBP1 might be developed to treat patients with HCC.
doi_str_mv 10.1093/carcin/bgw109
format Article
fullrecord <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1093_carcin_bgw109</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>27742690</sourcerecordid><originalsourceid>FETCH-LOGICAL-c398t-d564af5904de502d16b0bb3f97dc832cc42db6936c456a1f22d2a6e3337b16643</originalsourceid><addsrcrecordid>eNo9kM1OwzAQhC0EoqVw5Ir8AqH-i1MfoaKAFAkOII7R2lmnQSmpbAfE25MqwGk0q0-7O0PIJWfXnBm5dBBc-7G0zddoj8icK80ywVfsmMwZVzKTUqoZOYvxnTGuZW5OyUwUhRLasDlpyz5G2nu6uX3m1INruzZBwkihaQLG2H4i9QhpGM2B2-IeUu-w64YOAp3O9zugh1GkaRv6odmOivQNgh1CQ9F7dOmcnHjoIl786oK8bu5e1g9Z-XT_uL4pMyfNKmV1rhX43DBVY85EzbVl1kpvitqtpHBOidpqI7VTuQbuhagFaBxTFpZrreSCZNNeF8ZoAX21D-0OwnfFWXWorJp-rqbKRv5q4veD3WH9T_91JH8AnGhq4g</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Loss of FBP1 facilitates aggressive features of hepatocellular carcinoma cells through the Warburg effect</title><source>Oxford University Press Journals All Titles (1996-Current)</source><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Yang, Juan ; Wang, Cun ; Zhao, Fengbo ; Luo, Xiaoying ; Qin, Meilin ; Arunachalam, Einthavy ; Ge, Zhouhong ; Wang, Ning ; Deng, Xuan ; Jin, Guangzhi ; Cong, Wenming ; Qin, Wenxin</creator><creatorcontrib>Yang, Juan ; Wang, Cun ; Zhao, Fengbo ; Luo, Xiaoying ; Qin, Meilin ; Arunachalam, Einthavy ; Ge, Zhouhong ; Wang, Ning ; Deng, Xuan ; Jin, Guangzhi ; Cong, Wenming ; Qin, Wenxin</creatorcontrib><description>Reprogrammed metabolism has been identified as an emerging hallmark in cancer cells. It has been demonstrated that fructose-1, 6-bisphosphatase 1 (FBP1) as a rate-limiting enzyme in gluconeogenesis plays critical roles in tumor initiation and progression in several cancer types. However, function of FBP1 in hepatocellular carcinoma (HCC) is still not clear. In this study, we observed that the expression of FBP1 was obviously downregulated in the cell lines and tissues of HCC. Downregulation of FBP1 in HCC tissues was correlated with a lower overall survival rate and had a relatively higher tendency of tumor recurrence (n = 224). Silencing FBP1 could significantly promote colony formation, proliferation and metastasis of HCC cells, while ectopic overexpression of FBP1 resulted in impaired abilities of colony formation, proliferation and metastasis in vitro and in vivo. Mechanistically, silencing FBP1 facilitated glycolysis in HCC cell lines, which may be responsible for aggressiveness of HCC cells. We further found that targeting the Warburg effect using the specific inhibitor FX11 could suppress the aggressiveness of HCC cells which was mediated by loss of FBP1. These findings indicate that FBP1 appears to be a tumor suppressor in HCC. Strategies to restore the levels and activities of FBP1 might be developed to treat patients with HCC.</description><identifier>ISSN: 0143-3334</identifier><identifier>EISSN: 1460-2180</identifier><identifier>DOI: 10.1093/carcin/bgw109</identifier><identifier>PMID: 27742690</identifier><language>eng</language><publisher>England</publisher><subject>Animals ; Carcinoma, Hepatocellular - drug therapy ; Carcinoma, Hepatocellular - genetics ; Carcinoma, Hepatocellular - pathology ; Cell Proliferation - genetics ; Cell Transformation, Neoplastic - genetics ; Disease Progression ; DNA Helicases - antagonists &amp; inhibitors ; DNA Helicases - genetics ; DNA-Binding Proteins - antagonists &amp; inhibitors ; DNA-Binding Proteins - genetics ; Gene Expression Regulation, Neoplastic ; Gene Silencing ; Gluconeogenesis - drug effects ; Gluconeogenesis - genetics ; Hep G2 Cells ; Humans ; Liver Neoplasms - drug therapy ; Liver Neoplasms - genetics ; Liver Neoplasms - pathology ; Mice ; Naphthalenes - administration &amp; dosage ; Neoplasm Metastasis ; Xenograft Model Antitumor Assays</subject><ispartof>Carcinogenesis (New York), 2017-02, Vol.38 (2), p.134</ispartof><rights>The Author 2016. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c398t-d564af5904de502d16b0bb3f97dc832cc42db6936c456a1f22d2a6e3337b16643</citedby><cites>FETCH-LOGICAL-c398t-d564af5904de502d16b0bb3f97dc832cc42db6936c456a1f22d2a6e3337b16643</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27742690$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Yang, Juan</creatorcontrib><creatorcontrib>Wang, Cun</creatorcontrib><creatorcontrib>Zhao, Fengbo</creatorcontrib><creatorcontrib>Luo, Xiaoying</creatorcontrib><creatorcontrib>Qin, Meilin</creatorcontrib><creatorcontrib>Arunachalam, Einthavy</creatorcontrib><creatorcontrib>Ge, Zhouhong</creatorcontrib><creatorcontrib>Wang, Ning</creatorcontrib><creatorcontrib>Deng, Xuan</creatorcontrib><creatorcontrib>Jin, Guangzhi</creatorcontrib><creatorcontrib>Cong, Wenming</creatorcontrib><creatorcontrib>Qin, Wenxin</creatorcontrib><title>Loss of FBP1 facilitates aggressive features of hepatocellular carcinoma cells through the Warburg effect</title><title>Carcinogenesis (New York)</title><addtitle>Carcinogenesis</addtitle><description>Reprogrammed metabolism has been identified as an emerging hallmark in cancer cells. It has been demonstrated that fructose-1, 6-bisphosphatase 1 (FBP1) as a rate-limiting enzyme in gluconeogenesis plays critical roles in tumor initiation and progression in several cancer types. However, function of FBP1 in hepatocellular carcinoma (HCC) is still not clear. In this study, we observed that the expression of FBP1 was obviously downregulated in the cell lines and tissues of HCC. Downregulation of FBP1 in HCC tissues was correlated with a lower overall survival rate and had a relatively higher tendency of tumor recurrence (n = 224). Silencing FBP1 could significantly promote colony formation, proliferation and metastasis of HCC cells, while ectopic overexpression of FBP1 resulted in impaired abilities of colony formation, proliferation and metastasis in vitro and in vivo. Mechanistically, silencing FBP1 facilitated glycolysis in HCC cell lines, which may be responsible for aggressiveness of HCC cells. We further found that targeting the Warburg effect using the specific inhibitor FX11 could suppress the aggressiveness of HCC cells which was mediated by loss of FBP1. These findings indicate that FBP1 appears to be a tumor suppressor in HCC. Strategies to restore the levels and activities of FBP1 might be developed to treat patients with HCC.</description><subject>Animals</subject><subject>Carcinoma, Hepatocellular - drug therapy</subject><subject>Carcinoma, Hepatocellular - genetics</subject><subject>Carcinoma, Hepatocellular - pathology</subject><subject>Cell Proliferation - genetics</subject><subject>Cell Transformation, Neoplastic - genetics</subject><subject>Disease Progression</subject><subject>DNA Helicases - antagonists &amp; inhibitors</subject><subject>DNA Helicases - genetics</subject><subject>DNA-Binding Proteins - antagonists &amp; inhibitors</subject><subject>DNA-Binding Proteins - genetics</subject><subject>Gene Expression Regulation, Neoplastic</subject><subject>Gene Silencing</subject><subject>Gluconeogenesis - drug effects</subject><subject>Gluconeogenesis - genetics</subject><subject>Hep G2 Cells</subject><subject>Humans</subject><subject>Liver Neoplasms - drug therapy</subject><subject>Liver Neoplasms - genetics</subject><subject>Liver Neoplasms - pathology</subject><subject>Mice</subject><subject>Naphthalenes - administration &amp; dosage</subject><subject>Neoplasm Metastasis</subject><subject>Xenograft Model Antitumor Assays</subject><issn>0143-3334</issn><issn>1460-2180</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo9kM1OwzAQhC0EoqVw5Ir8AqH-i1MfoaKAFAkOII7R2lmnQSmpbAfE25MqwGk0q0-7O0PIJWfXnBm5dBBc-7G0zddoj8icK80ywVfsmMwZVzKTUqoZOYvxnTGuZW5OyUwUhRLasDlpyz5G2nu6uX3m1INruzZBwkihaQLG2H4i9QhpGM2B2-IeUu-w64YOAp3O9zugh1GkaRv6odmOivQNgh1CQ9F7dOmcnHjoIl786oK8bu5e1g9Z-XT_uL4pMyfNKmV1rhX43DBVY85EzbVl1kpvitqtpHBOidpqI7VTuQbuhagFaBxTFpZrreSCZNNeF8ZoAX21D-0OwnfFWXWorJp-rqbKRv5q4veD3WH9T_91JH8AnGhq4g</recordid><startdate>20170201</startdate><enddate>20170201</enddate><creator>Yang, Juan</creator><creator>Wang, Cun</creator><creator>Zhao, Fengbo</creator><creator>Luo, Xiaoying</creator><creator>Qin, Meilin</creator><creator>Arunachalam, Einthavy</creator><creator>Ge, Zhouhong</creator><creator>Wang, Ning</creator><creator>Deng, Xuan</creator><creator>Jin, Guangzhi</creator><creator>Cong, Wenming</creator><creator>Qin, Wenxin</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>20170201</creationdate><title>Loss of FBP1 facilitates aggressive features of hepatocellular carcinoma cells through the Warburg effect</title><author>Yang, Juan ; Wang, Cun ; Zhao, Fengbo ; Luo, Xiaoying ; Qin, Meilin ; Arunachalam, Einthavy ; Ge, Zhouhong ; Wang, Ning ; Deng, Xuan ; Jin, Guangzhi ; Cong, Wenming ; Qin, Wenxin</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c398t-d564af5904de502d16b0bb3f97dc832cc42db6936c456a1f22d2a6e3337b16643</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Animals</topic><topic>Carcinoma, Hepatocellular - drug therapy</topic><topic>Carcinoma, Hepatocellular - genetics</topic><topic>Carcinoma, Hepatocellular - pathology</topic><topic>Cell Proliferation - genetics</topic><topic>Cell Transformation, Neoplastic - genetics</topic><topic>Disease Progression</topic><topic>DNA Helicases - antagonists &amp; inhibitors</topic><topic>DNA Helicases - genetics</topic><topic>DNA-Binding Proteins - antagonists &amp; inhibitors</topic><topic>DNA-Binding Proteins - genetics</topic><topic>Gene Expression Regulation, Neoplastic</topic><topic>Gene Silencing</topic><topic>Gluconeogenesis - drug effects</topic><topic>Gluconeogenesis - genetics</topic><topic>Hep G2 Cells</topic><topic>Humans</topic><topic>Liver Neoplasms - drug therapy</topic><topic>Liver Neoplasms - genetics</topic><topic>Liver Neoplasms - pathology</topic><topic>Mice</topic><topic>Naphthalenes - administration &amp; dosage</topic><topic>Neoplasm Metastasis</topic><topic>Xenograft Model Antitumor Assays</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Yang, Juan</creatorcontrib><creatorcontrib>Wang, Cun</creatorcontrib><creatorcontrib>Zhao, Fengbo</creatorcontrib><creatorcontrib>Luo, Xiaoying</creatorcontrib><creatorcontrib>Qin, Meilin</creatorcontrib><creatorcontrib>Arunachalam, Einthavy</creatorcontrib><creatorcontrib>Ge, Zhouhong</creatorcontrib><creatorcontrib>Wang, Ning</creatorcontrib><creatorcontrib>Deng, Xuan</creatorcontrib><creatorcontrib>Jin, Guangzhi</creatorcontrib><creatorcontrib>Cong, Wenming</creatorcontrib><creatorcontrib>Qin, Wenxin</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>Carcinogenesis (New York)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Yang, Juan</au><au>Wang, Cun</au><au>Zhao, Fengbo</au><au>Luo, Xiaoying</au><au>Qin, Meilin</au><au>Arunachalam, Einthavy</au><au>Ge, Zhouhong</au><au>Wang, Ning</au><au>Deng, Xuan</au><au>Jin, Guangzhi</au><au>Cong, Wenming</au><au>Qin, Wenxin</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Loss of FBP1 facilitates aggressive features of hepatocellular carcinoma cells through the Warburg effect</atitle><jtitle>Carcinogenesis (New York)</jtitle><addtitle>Carcinogenesis</addtitle><date>2017-02-01</date><risdate>2017</risdate><volume>38</volume><issue>2</issue><spage>134</spage><pages>134-</pages><issn>0143-3334</issn><eissn>1460-2180</eissn><abstract>Reprogrammed metabolism has been identified as an emerging hallmark in cancer cells. It has been demonstrated that fructose-1, 6-bisphosphatase 1 (FBP1) as a rate-limiting enzyme in gluconeogenesis plays critical roles in tumor initiation and progression in several cancer types. However, function of FBP1 in hepatocellular carcinoma (HCC) is still not clear. In this study, we observed that the expression of FBP1 was obviously downregulated in the cell lines and tissues of HCC. Downregulation of FBP1 in HCC tissues was correlated with a lower overall survival rate and had a relatively higher tendency of tumor recurrence (n = 224). Silencing FBP1 could significantly promote colony formation, proliferation and metastasis of HCC cells, while ectopic overexpression of FBP1 resulted in impaired abilities of colony formation, proliferation and metastasis in vitro and in vivo. Mechanistically, silencing FBP1 facilitated glycolysis in HCC cell lines, which may be responsible for aggressiveness of HCC cells. We further found that targeting the Warburg effect using the specific inhibitor FX11 could suppress the aggressiveness of HCC cells which was mediated by loss of FBP1. These findings indicate that FBP1 appears to be a tumor suppressor in HCC. Strategies to restore the levels and activities of FBP1 might be developed to treat patients with HCC.</abstract><cop>England</cop><pmid>27742690</pmid><doi>10.1093/carcin/bgw109</doi><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0143-3334
ispartof Carcinogenesis (New York), 2017-02, Vol.38 (2), p.134
issn 0143-3334
1460-2180
language eng
recordid cdi_crossref_primary_10_1093_carcin_bgw109
source Oxford University Press Journals All Titles (1996-Current); MEDLINE; EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection
subjects Animals
Carcinoma, Hepatocellular - drug therapy
Carcinoma, Hepatocellular - genetics
Carcinoma, Hepatocellular - pathology
Cell Proliferation - genetics
Cell Transformation, Neoplastic - genetics
Disease Progression
DNA Helicases - antagonists & inhibitors
DNA Helicases - genetics
DNA-Binding Proteins - antagonists & inhibitors
DNA-Binding Proteins - genetics
Gene Expression Regulation, Neoplastic
Gene Silencing
Gluconeogenesis - drug effects
Gluconeogenesis - genetics
Hep G2 Cells
Humans
Liver Neoplasms - drug therapy
Liver Neoplasms - genetics
Liver Neoplasms - pathology
Mice
Naphthalenes - administration & dosage
Neoplasm Metastasis
Xenograft Model Antitumor Assays
title Loss of FBP1 facilitates aggressive features of hepatocellular carcinoma cells through the Warburg effect
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-08T15%3A40%3A53IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Loss%20of%20FBP1%20facilitates%20aggressive%20features%20of%20hepatocellular%20carcinoma%20cells%20through%20the%20Warburg%20effect&rft.jtitle=Carcinogenesis%20(New%20York)&rft.au=Yang,%20Juan&rft.date=2017-02-01&rft.volume=38&rft.issue=2&rft.spage=134&rft.pages=134-&rft.issn=0143-3334&rft.eissn=1460-2180&rft_id=info:doi/10.1093/carcin/bgw109&rft_dat=%3Cpubmed_cross%3E27742690%3C/pubmed_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/27742690&rfr_iscdi=true